Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
WeightWatchers stock rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...
WW surge after GLP-1 compounding announcement not justified after study, Barclays says
A recently released negative study by Novo Nordisk (NVO) on the differences between its own semaglutide and liraglutide ...
Drug makers can’t make knockoff weight-loss drugs anymore—and they’re mad
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
What's Going With WeightWatchers Stock On Wednesday?
WeightWatchers stock rises after the company announces compounded semaglutide offerings, addressing GLP-1 shortages while ...
Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
(THE CONVERSATION) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to ...
WeightWatchers offering compounded version of Ozempic, despite concerns expressed by FDA
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA ...
bovnews1d
WeightWatchers (WW) Surges in Premarket Trading: A Closer Look at Recent Developments
WeightWatchers recently announced the inclusion of compounded semaglutide into its suite of offerings. This new clinical weight management intervention aims to broaden access for eligible members who ...
WeightWatchers Adds Compounded GLP-1, Expanding Accessibility and Affordability of Weight Loss Medications
WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight ...
Hold Rating on WW International Amid New Semaglutide Offering and Optimistic Revenue Projections
In a report released today, Alex Fuhrman from Craig-Hallum maintained a Hold rating on WW International (WW – Research Report), with a ...